229 related articles for article (PubMed ID: 35207500)
21. Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa.
Ciurescu D; Condruz S; Irimie M
Acta Dermatovenerol Alp Pannonica Adriat; 2024 May; 33(3):actaapa.2024.14. PubMed ID: 38808531
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous squamous cell carcinoma developing from recessive dystrophic epidermolysis bullosa: a case report and an immunohistochemical study.
Tsukada A; Fujimura T; Furudate S; Kambayashi Y; Numata Y; Haga T; Hashimoto A; Aiba S
Case Rep Dermatol; 2012 Sep; 4(3):197-201. PubMed ID: 23271994
[TBL] [Abstract][Full Text] [Related]
23. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
[TBL] [Abstract][Full Text] [Related]
24. Cord Blood-Derived Stem Cells Suppress Fibrosis and May Prevent Malignant Progression in Recessive Dystrophic Epidermolysis Bullosa.
Liao Y; Ivanova L; Zhu H; Plumer T; Hamby C; Mehta B; Gevertz A; Christiano AM; McGrath JA; Cairo MS
Stem Cells; 2018 Dec; 36(12):1839-1850. PubMed ID: 30247783
[TBL] [Abstract][Full Text] [Related]
25. T-cell activation and bacterial infection in skin wounds of recessive dystrophic epidermolysis bullosa patients.
Alexeev V; Huitema L; Phillips T; Cepeda R; de Los Cobos D; Perez RIM; Salas-Garza M; Fajardo-Ramirez OR; Ringpfeil F; Uitto J; Salas-Alanis JC; Igoucheva O
Exp Dermatol; 2022 Sep; 31(9):1431-1442. PubMed ID: 35620886
[TBL] [Abstract][Full Text] [Related]
26. Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma.
Lee CAA; Wu S; Chow YT; Kofman E; Williams V; Riddle M; Eide C; Ebens CL; Frank MH; Tolar J; Hook KP; AlDubayan SH; Frank NY
J Invest Dermatol; 2024 Jan; ():. PubMed ID: 38272206
[TBL] [Abstract][Full Text] [Related]
27. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
[TBL] [Abstract][Full Text] [Related]
28. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.
Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C
J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465
[TBL] [Abstract][Full Text] [Related]
29. Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa.
Khaddour K; Gorell ES; Dehdashti F; Tang JY; Ansstas G
Case Rep Oncol; 2020; 13(2):911-915. PubMed ID: 32884539
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
[TBL] [Abstract][Full Text] [Related]
31. YAP1/Piezo1 involve in the dynamic changes of lymphatic vessels in UVR-induced photoaging progress to squamous cell carcinoma.
Yang YL; Zhou C; Chen Q; Shen SZ; Li JD; Wang XL; Wang PR
J Transl Med; 2023 Nov; 21(1):820. PubMed ID: 37974224
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
[TBL] [Abstract][Full Text] [Related]
34. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
35. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
Tartaglia G; Cao Q; Padron ZM; South AP
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
[TBL] [Abstract][Full Text] [Related]
36. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
[TBL] [Abstract][Full Text] [Related]
38. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
39. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
[TBL] [Abstract][Full Text] [Related]
40. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
